Arteris (AIP) VP and General Counsel exercises options, sells 5,000 shares

Rhea-AI Filing Summary

Arteris, Inc. VP and General Counsel Paul L. Alpern reported an automatic option exercise and share sale in Arteris, Inc. common stock. On February 2, 2026, he exercised options for 5,000 shares at an exercise price of $0.56 per share and then sold 5,000 shares of common stock at a weighted average price of $15.4753 per share.

The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 5, 2025. Following these transactions, Alpern beneficially owned 57,650 shares of Arteris common stock directly, and 65,000 derivative securities (stock options) remained outstanding with an exercise price of $0.56 per share, expiring on October 23, 2029.

Insider Trade Summary

Net Seller: 5,000 shares ($77,377)

Net Sell 3 txns

Insider Alpern Paul L

Role VP and General Counsel

Sold 5,000 shs ($77K)

Type	Security	Shares	Price	Value
Exercise	Common Stock	5,000	$0.00	--
Exercise	Common Stock	5,000	$0.56	$3K
Sale	Common Stock	5,000	$15.4753	$77K

Holdings After Transaction: Common Stock — 65,000 shares (Direct)

Footnotes (1)

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on June 5, 2025. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.93 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the total shares vested on August 26, 2020; thereafter, 1/48th of the total shares vested monthly for 3 years, beginning on September 26,2020.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alpern Paul L

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CA 95008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP and General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		M(1)		5,000	A	$0.56	62,650	D
Common Stock	02/02/2026		S(1)		5,000	D	$15.4753(2)	57,650	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock	$0.56	02/02/2026		M			5,000(1)	(3)	10/23/2029	Common Stock	5,000	$0.00	65,000	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on June 5, 2025.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.93 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. 25% of the total shares vested on August 26, 2020; thereafter, 1/48th of the total shares vested monthly for 3 years, beginning on September 26,2020.

Remarks:

	/s/ Paul Alpern	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arteris (AIP) report for Paul L. Alpern?

Arteris reported that VP and General Counsel Paul L. Alpern exercised options for 5,000 shares at $0.56 and sold 5,000 common shares at a weighted average price of $15.4753 on February 2, 2026, under a pre-arranged 10b5-1 trading plan.

How many Arteris (AIP) shares does Paul L. Alpern own after this Form 4?

After the reported transactions, Paul L. Alpern beneficially owned 57,650 shares of Arteris common stock directly. He also held 65,000 derivative securities (stock options) with a $0.56 exercise price, scheduled to expire on October 23, 2029, according to the Form 4 disclosure.

Was the Arteris (AIP) insider sale by Paul L. Alpern under a 10b5-1 plan?

Yes. The Form 4 states the transaction was made under a Rule 10b5-1 trading plan adopted by Paul L. Alpern on June 5, 2025. Such plans pre-schedule trades, aiming to separate routine selling from day-to-day market or company developments.

At what prices did Paul L. Alpern sell Arteris (AIP) shares on February 2, 2026?

The Form 4 reports a weighted average sale price of $15.4753 per share. Footnotes state the 5,000 shares were sold in multiple trades at prices ranging from $15.05 to $15.93 inclusive, with full breakdowns available upon request to the company or regulators.

What stock options did Paul L. Alpern exercise in the Arteris (AIP) Form 4?

He exercised stock options covering 5,000 shares of Arteris common stock at an exercise price of $0.56 on February 2, 2026. These options are part of a grant that vested beginning August 26, 2020, with monthly vesting continuing for three years thereafter.

How did Paul L. Alpern’s Arteris (AIP) option grant vest over time?

According to the footnotes, 25% of the total option shares vested on August 26, 2020. The remaining 75% vested in equal monthly installments of 1/48th of the total shares over three years, beginning on September 26, 2020, until fully vested.